If you are suffering from a sleep disorder such as obstructive sleep apnea or narcolepsy, you would know that both these disorders can cause excessive daytime sleepiness. This is a debilitating side effect that can adversely affect your quality of life as it limits the amount of work you can do during the day.
A clinical trial
was conducted recently to check whether a medication called solriamfetol is safe and effective in treating excessive daytime sleepiness in obstructive sleep apnea and narcolepsy.
Obstructive sleep apnea (OSA) occurs when the muscles that support the soft tissues in your throat, such as your tongue and soft palate, temporarily relax. This causes your airway to be narrowed or closed resulting in obstruction of your breathing. Narcolepsy is a rare long-term brain condition that can prevent a person from choosing when to wake or sleep. The brain is unable to regulate sleeping and waking patterns normally.
Both these sleep disorders can result in excessive daytime sleepiness. Solriamfetol is a medication that is used to treat excessive daytime sleepiness in these conditions. However, there is a concern about its safety since it can cause several side effects.
A clinical trial was conducted recently to determine the occurrence and duration of common side effects of solriamfetol in patients with obstructive sleep apnea and narcolepsy.
The clinical study, which was published in the Journal of Clinical Sleep Medicine, involved 710 participants suffering from OSA and narcolepsy. 474 patients were suffering from OSA and 276 patients from narcolepsy. These patients were divided into two groups. One group received solriamfetol treatment while the other group received a placebo.
The results of the clinical study showed that in patients taking solriamfetol headache occurred in 5.1% of patients with OSA compared to 8.5% of patients with narcolepsy. Nausea occurred in 2.5% of patients with OSA compared to 4.2% of patients with narcolepsy. Other side effects included decreased appetite, anxiety, insomnia, feeling jittery, and dry mouth. The rate of these side effects was higher in the solriamfetol group compared to the group that did not take this drug.
However, the clinical study showed that these adverse events were generally mild to moderate in severity and of limited duration. They were highest during the first week and decreased after that. The duration of most of these side effects was less than 8 days.
In conclusion, the clinical study provides important information about the safety and tolerability of solriamfetol in the treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy. It emphasizes that solriamfetol is a safe and effective treatment for treating excessive daytime sleepiness in patients with OSA and narcolepsy.